Orlando, Fla.—While some patients are unwilling to accept any degree of breast cancer risk as a trade-off for less invasive treatment of ductal carcinoma in situ, the majority of participants in one recent experiment were willing to shoulder some degree of risk if it meant mitigating some treatment-related side issues.
There has been a lot of discussion about potentially de-escalating therapy for DCIS, but little is known about patient preference and how many women would